AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 81 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2022. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,861,600 | +332.9% | 260,000 | +203.2% | 0.10% | +284.0% |
| Q3 2022 | $430,000 | -77.7% | 85,758 | -89.1% | 0.02% | -77.7% |
| Q2 2022 | $1,926,000 | +62.4% | 789,181 | +347.9% | 0.11% | +202.7% |
| Q2 2021 | $1,186,000 | -44.0% | 176,206 | -24.7% | 0.04% | -38.3% |
| Q1 2021 | $2,116,000 | -18.7% | 234,122 | -39.9% | 0.06% | -36.8% |
| Q4 2020 | $2,602,000 | -35.1% | 389,571 | -51.0% | 0.10% | -54.1% |
| Q3 2020 | $4,008,000 | -11.9% | 795,200 | +41.3% | 0.21% | -52.6% |
| Q2 2020 | $4,547,000 | +15.3% | 562,800 | +13.3% | 0.44% | -6.6% |
| Q1 2020 | $3,943,000 | +379.1% | 496,660 | +355.7% | 0.47% | +550.0% |
| Q4 2019 | $823,000 | +63.0% | 109,000 | -10.2% | 0.07% | -16.3% |
| Q3 2019 | $505,000 | – | 121,435 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |